TrialSafety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Trial details
- Registry ID
- NCT04642638
- Phase
- Phase 2, Phase 3
Drug research
CELLECTRA® 2000
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureNCT04642638 | Inovio Pharmaceuticals | Phase 2, Phase 3 | Terminated | 2022-09-13Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |